{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:02:28Z","timestamp":1789808548961,"version":"4.0.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Tianjin Health Research Project","award":["TJWJ2025MS023"],"award-info":[{"award-number":["TJWJ2025MS023"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"DOI":"10.1007\/s00406-026-02382-z","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T06:26:07Z","timestamp":1789799167000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gender differences in cognitive function in antipsychotic-treated chronic schizophrenia patients with hyperprolactinemia: a large-scale cross-sectional study"],"prefix":"10.1007","author":[{"given":"Yi","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haizhu","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0286-4369","authenticated-orcid":false,"given":"Guoshuai","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"issue":"1","key":"2382_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1615\/CritRevNeurobiol.v14.i1.10","volume":"14","author":"B Elvev\u00e5g","year":"2000","unstructured":"Elvev\u00e5g B, Goldberg TE (2000) Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 14(1):1\u201321","journal-title":"Crit Rev Neurobiol"},{"issue":"1","key":"2382_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40779-022-00420-0","volume":"9","author":"MH Zhu","year":"2022","unstructured":"Zhu MH, Liu ZJ, Hu QY, Yang JY, Jin Y, Zhu N, Huang Y, Shi DH, Liu MJ, Tan HY et al (2022) Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial. Mil Med Res 9(1):59","journal-title":"Military Med Res"},{"issue":"1","key":"2382_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/schbul\/21.1.1","volume":"21","author":"DJ Castle","year":"1995","unstructured":"Castle DJ, Abel K, Takei N, Murray RM (1995) Gender differences in schizophrenia: hormonal effect or subtypes? Schizophr Bull 21(1):1\u201312","journal-title":"Schizophr Bull"},{"issue":"10","key":"2382_CR4","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1176\/ajp.155.10.1358","volume":"155","author":"JM Goldstein","year":"1998","unstructured":"Goldstein JM, Seidman LJ, Goodman JM, Koren D, Lee H, Weintraub S, Tsuang MT (1998) Are there sex differences in neuropsychological functions among patients with schizophrenia? Am J Psychiatry 155(10):1358\u20131364","journal-title":"Am J Psychiatry"},{"issue":"3","key":"2382_CR5","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1176\/appi.ajp.163.3.470","volume":"163","author":"DJ Walder","year":"2006","unstructured":"Walder DJ, Seidman LJ, Cullen N, Su J, Tsuang MT, Goldstein JM (2006) Sex differences in language dysfunction in schizophrenia. Am J Psychiatry 163(3):470\u2013477","journal-title":"Am J Psychiatry"},{"issue":"1","key":"2382_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/oxfordjournals.schbul.a006850","volume":"27","author":"PJ Moriarty","year":"2001","unstructured":"Moriarty PJ, Lieber D, Bennett A, White L, Parrella M, Harvey PD, Davis KL (2001) Gender differences in poor outcome patients with lifelong schizophrenia. Schizophr Bull 27(1):103\u2013113","journal-title":"Schizophr Bull"},{"issue":"10","key":"2382_CR7","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1176\/ajp.155.10.1437","volume":"155","author":"AL Hoff","year":"1998","unstructured":"Hoff AL, Wieneke M, Faustman WO, Horon R, Sakuma M, Blankfeld H, Espinoza S, DeLisi LE (1998) Sex differences in neuropsychological functioning of first-episode and chronically ill schizophrenic patients. Am J Psychiatry 155(10):1437\u20131439","journal-title":"Am J Psychiatry"},{"issue":"9","key":"2382_CR8","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1176\/ajp.153.9.1178","volume":"153","author":"RR Lewine","year":"1996","unstructured":"Lewine RR, Walker EF, Shurett R, Caudle J, Haden C (1996) Sex differences in neuropsychological functioning among schizophrenic patients. Am J Psychiatry 153(9):1178\u20131184","journal-title":"Am J Psychiatry"},{"key":"2382_CR9","doi-asserted-by":"publisher","first-page":"107112","DOI":"10.1016\/j.psyneuen.2024.107112","volume":"169","author":"T Jord\u00e0-Baleri","year":"2024","unstructured":"Jord\u00e0-Baleri T, Garriga M, Mezquida G, Cuesta MJ, Martinez-Aran A, Garcia-Rizo C, Lobo A, Gonz\u00e1lez-Pinto A, Diaz-Caneja CM, Rold\u00e1n A et al (2024) Sex differences in prolactin levels and clinical outcomes in patients with a first psychotic episode. Psychoneuroendocrinology 169:107112","journal-title":"Psychoneuroendocrinology"},{"key":"2382_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.schres.2017.02.010","volume":"189","author":"S Ittig","year":"2017","unstructured":"Ittig S, Studerus E, Heitz U, Menghini-M\u00fcller S, Beck K, Egloff L, Leanza L, Andreou C, Riecher-R\u00f6ssler A (2017) Sex differences in prolactin levels in emerging psychosis: indication for enhanced stress reactivity in women. Schizophr Res 189:111\u2013116","journal-title":"Schizophr Res"},{"issue":"6","key":"2382_CR11","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1177\/0004867417744254","volume":"52","author":"I Montalvo","year":"2018","unstructured":"Montalvo I, Nadal R, Armario A, Guti\u00e9rrez-Zotes A, Creus M, Cabezas \u00c1, Sol\u00e9 M, Algora MJ, S\u00e1nchez-Gistau V, Vilella E et al (2018) Sex differences in the relationship between prolactin levels and impaired processing speed in early psychosis. Aust N Z J Psychiatry 52(6):585\u2013595","journal-title":"Aust N Z J Psychiatry"},{"issue":"1","key":"2382_CR12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/cen.13156","volume":"86","author":"E Soto-Pedre","year":"2017","unstructured":"Soto-Pedre E, Newey PJ, Bevan JS, Greig N, Leese GP (2017) The epidemiology of hyperprolactinaemia over 20 years in the Tayside region of Scotland: the Prolactin Epidemiology, Audit and Research Study (PROLEARS). Clin Endocrinol 86(1):60\u201367","journal-title":"Clin Endocrinol"},{"issue":"3","key":"2382_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/13651501.2019.1576905","volume":"23","author":"JM Bonete Ll\u00e1cer","year":"2019","unstructured":"Bonete Ll\u00e1cer JM, Mart\u00ednez Hortelano A, Richart Albelda B (2019) Hyperprolactinemia in psychotic patients treated in monotherapy with long-acting injectable antipsychotics. Int J Psychiatry Clin Pract 23(3):189\u2013193","journal-title":"Int J psychiatry Clin Pract"},{"issue":"4","key":"2382_CR14","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1080\/13651501.2018.1425459","volume":"22","author":"FD Alosaimi","year":"2018","unstructured":"Alosaimi FD, Fallata EO, Abalhassan M, Alhabbad A, Alzain N, Alhaddad B, Alassiry MZ (2018) Prevalence and risk factors of hyperprolactinemia among patients with various psychiatric diagnoses and medications. Int J Psychiatry Clin Pract 22(4):274\u2013281","journal-title":"Int J psychiatry Clin Pract"},{"key":"2382_CR15","doi-asserted-by":"publisher","first-page":"718800","DOI":"10.3389\/fphar.2021.718800","volume":"12","author":"TH Wu","year":"2021","unstructured":"Wu TH, Lin CH, Goh KK, Chen CY, Chen CH, Lane HY, Lu ML (2021) The relationships between hyperprolactinemia, metabolic disturbance, and sexual dysfunction in patients with schizophrenia under olanzapine treatment. Front Pharmacol 12:718800","journal-title":"Front Pharmacol"},{"key":"2382_CR16","doi-asserted-by":"publisher","first-page":"742","DOI":"10.3389\/fneur.2017.00742","volume":"8","author":"S Yao","year":"2017","unstructured":"Yao S, Song J, Gao J, Lin P, Yang M, Zahid KR, Yan Y, Cao C, Ma P, Zhang H et al (2017) Cognitive function and serum hormone levels are associated with gray matter volume decline in female patients with prolactinomas. Front Neurol 8:742","journal-title":"Front Neurol"},{"key":"2382_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000486000","volume":"49","author":"M Andersen","year":"2018","unstructured":"Andersen M, Glintborg D (2018) Metabolic syndrome in hyperprolactinemia. Front Horm Res 49:29\u201347","journal-title":"Front Horm Res"},{"key":"2382_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.bbi.2014.04.001","volume":"42","author":"AA Miller","year":"2014","unstructured":"Miller AA, Spencer SJ (2014) Obesity and neuroinflammation: a pathway to cognitive impairment. Brain Behav Immun 42:10\u201321","journal-title":"Brain Behav Immun"},{"issue":"7","key":"2382_CR19","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1177\/0269881107078281","volume":"21","author":"C Bushe","year":"2007","unstructured":"Bushe C, Shaw M (2007) Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol (Oxford England) 21(7):768\u2013773","journal-title":"J Psychopharmacol (Oxford England)"},{"key":"2382_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.psychres.2019.02.017","volume":"274","author":"SW D\u00fcring","year":"2019","unstructured":"D\u00fcring SW, Nielsen M, Bak N, Glenth\u00f8j BY, Ebdrup BH (2019) Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D(2\/3) receptor blockade - an exploratory study. Psychiatry Res 274:58\u201365","journal-title":"Psychiatry Res"},{"issue":"6","key":"2382_CR21","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/jcp.0b013e31815ac4e5","volume":"27","author":"M Byerly","year":"2007","unstructured":"Byerly M, Suppes T, Tran QV, Baker RA (2007) Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol 27(6):639\u2013661","journal-title":"J Clin Psychopharmacol"},{"key":"2382_CR22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.schres.2020.04.031","volume":"222","author":"J Labad","year":"2020","unstructured":"Labad J, Montalvo I, Gonz\u00e1lez-Rodr\u00edguez A, Garc\u00eda-Rizo C, Crespo-Facorro B, Monreal JA, Palao D (2020) Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: a systematic review and meta-analysis. Schizophr Res 222:88\u201396","journal-title":"Schizophr Res"},{"issue":"Pt 4","key":"2382_CR23","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1258\/acb.2010.010025","volume":"47","author":"CJ Bushe","year":"2010","unstructured":"Bushe CJ, Bradley A, Pendlebury J (2010) A review of hyperprolactinaemia and severe mental illness: are there implications for clinical biochemistry? Ann Clin Biochem 47(Pt 4):292\u2013300","journal-title":"Ann Clin Biochem"},{"key":"2382_CR24","doi-asserted-by":"crossref","unstructured":"Chen A, Cao C, Liu B, Wang S, Wu S, Xu G, Song J (2022) Hyperprolactinemia associated with attentional processing and interference control impairments in patients with prolactinomas. Brain Sci 12(8)","DOI":"10.3390\/brainsci12081091"},{"key":"2382_CR25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.bbr.2013.05.031","volume":"252","author":"L Torner","year":"2013","unstructured":"Torner L, Tinajero E, Lajud N, Quintanar-St\u00e9phano A, Olvera-Cort\u00e9s E (2013) Hyperprolactinemia impairs object recognition without altering spatial learning in male rats. Behav Brain Res 252:32\u201339","journal-title":"Behav Brain Res"},{"issue":"6","key":"2382_CR26","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00737-024-01491-9","volume":"27","author":"BA Brand","year":"2024","unstructured":"Brand BA, de Boer JN, Willemse EJM, Weickert CS, Sommer IE, Weickert TW (2024) Antipsychotic-induced prolactin elevation in premenopausal women with schizophrenia: associations with estrogen, disease severity and cognition. Arch Women Ment Health 27(6):931\u2013941","journal-title":"Arch Women Ment Health"},{"key":"2382_CR27","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.schres.2024.06.022","volume":"270","author":"IMH Hamers","year":"2024","unstructured":"Hamers IMH, Brand BA, Begemann MJH, Weickert CS, Weickert TW, Sommer IEC (2024) The association of prolactin and gonadal hormones with cognition and symptoms in men with schizophrenia spectrum disorder: divergent effects of testosterone and estrogen. Schizophr Res 270:273\u2013280","journal-title":"Schizophr Res"},{"issue":"4","key":"2382_CR28","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00702-024-02748-4","volume":"131","author":"G Luo","year":"2024","unstructured":"Luo G, Bai F, Qu X, Jing Y, Wang S, Xuekelaiti Z, Yao C, Li M, Li J (2024) The relationship between serum prolactin levels and cognitive function in drug-na\u00efve schizophrenia patients: a cross-sectional study. J Neural Transm (Vienna Austria: 1996) 131(4):385\u2013391","journal-title":"J neural transmission (Vienna Austria: 1996)"},{"issue":"6","key":"2382_CR29","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S2213-8587(21)00045-0","volume":"9","author":"XF Pan","year":"2021","unstructured":"Pan XF, Wang L, Pan A (2021) Epidemiology and determinants of obesity in China. lancet Diabetes Endocrinol 9(6):373\u2013392","journal-title":"lancet Diabetes Endocrinol"},{"key":"2382_CR30","doi-asserted-by":"publisher","first-page":"1620700","DOI":"10.3389\/fpsyt.2025.1620700","volume":"16","author":"M Yang","year":"2025","unstructured":"Yang M, Li Z, Feng D (2025) Editorial: Brain pathology and rehabilitation mechanisms of neuromodulation in psychiatric disorders. Front Psychiatry 16:1620700","journal-title":"Front Psychiatry"},{"key":"2382_CR31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jpsychires.2025.05.052","volume":"189","author":"J Li","year":"2025","unstructured":"Li J, Lu X, Du S, Hu W, Xiao D, He B, Su C, Lin S, Zhan Q, Wu H et al (2025) Effects of varied rTMS frequencies on cognitive function in individuals with chronic schizophrenia: a double-blind randomized controlled trial. J Psychiatr Res 189:33\u201341","journal-title":"J Psychiatr Res"},{"issue":"6","key":"2382_CR32","doi-asserted-by":"publisher","first-page":"e5366","DOI":"10.1002\/bmc.5366","volume":"36","author":"Z Li","year":"2022","unstructured":"Li Z, Liu M, Chen C, Pan Y, Cui X, Sun J, Zhao F, Cao Y (2022) Simultaneous determination of serum homocysteine, cysteine, and methionine in patients with schizophrenia by liquid chromatography-tandem mass spectrometry. Biomed Chromatogr BMC 36(6):e5366","journal-title":"Biomedical chromatography: BMC"},{"key":"2382_CR33","doi-asserted-by":"crossref","unstructured":"Yang M, Cui X, Kong D, Huang X, Zhao G, Li X, Zhao H, Liu L, Yan F, Yang Y et al (2024) The efficacy of Lactobacillus and Bifidobacterium in patients with schizophrenia: a meta-analysis. Eur Arch Psychiatry Clin NeuroSci","DOI":"10.1007\/s00406-024-01935-4"},{"issue":"1","key":"2382_CR34","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12888-023-04711-1","volume":"23","author":"C Beainy","year":"2023","unstructured":"Beainy C, Haddad C, Fekih-Romdhane F, Hallit S, Haddad G (2023) Decreased insight, but not self-stigma or belief about medicine, is associated with greater severity of delusions in a sample of long-stay patients with schizophrenia: a cross-sectional study. BMC Psychiatry 23(1):222","journal-title":"BMC Psychiatry"},{"issue":"10202","key":"2382_CR35","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, Arndt T, B\u00e4ckers L, Rothe P, Cipriani A et al (2019) Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet (London England) 394(10202):939\u2013951","journal-title":"Lancet (London England)"},{"issue":"1","key":"2382_CR36","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","volume":"7","author":"T Pillinger","year":"2020","unstructured":"Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, Beck K, Natesan S, Efthimiou O, Cipriani A et al (2020) Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry 7(1):64\u201377","journal-title":"lancet Psychiatry"},{"key":"2382_CR37","doi-asserted-by":"publisher","first-page":"102732","DOI":"10.1016\/j.ajp.2021.102732","volume":"62","author":"K Lim","year":"2021","unstructured":"Lim K, Peh OH, Yang Z, Rekhi G, Rapisarda A, See YM, Rashid NAA, Ang MS, Lee SA, Sim K et al (2021) Large-scale evaluation of the positive and negative syndrome scale (PANSS) symptom architecture in schizophrenia. Asian J Psychiatry 62:102732","journal-title":"Asian J psychiatry"},{"issue":"3","key":"2382_CR38","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1076\/jcen.20.3.310.823","volume":"20","author":"C Randolph","year":"1998","unstructured":"Randolph C, Tierney MC, Mohr E, Chase TN (1998) The repeatable battery for the assessment of neuropsychological status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 20(3):310\u2013319","journal-title":"J Clin Exp Neuropsychol"},{"issue":"12","key":"2382_CR39","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1017\/S0033291719001685","volume":"49","author":"E Bora","year":"2019","unstructured":"Bora E (2019) Peripheral inflammatory and neurotrophic biomarkers of cognitive impairment in schizophrenia: a meta-analysis. Psychol Med 49(12):1971\u20131979","journal-title":"Psychol Med"},{"issue":"9","key":"2382_CR40","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1038\/npp.2011.65","volume":"36","author":"C de la Fuente-Sandoval","year":"2011","unstructured":"de la Fuente-Sandoval C, Le\u00f3n-Ortiz P, Favila R, Stephano S, Mamo D, Ram\u00edrez-Berm\u00fadez J, Graff-Guerrero A (2011) Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology 36(9):1781\u20131791","journal-title":"Neuropsychopharmacology: official publication Am Coll Neuropsychopharmacol"},{"issue":"1","key":"2382_CR41","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jadohealth.2008.11.010","volume":"45","author":"JM Jerrell","year":"2009","unstructured":"Jerrell JM, Bacon J, Burgis JT, Menon S (2009) Hyperprolactinemia-related adverse events associated with antipsychotic treatment in children and adolescents. J Adolesc Health 45(1):70\u201376","journal-title":"J Adolesc health: official publication Soc Adolesc Med"},{"issue":"4","key":"2382_CR42","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/ageing\/afh100","volume":"33","author":"LB Hassing","year":"2004","unstructured":"Hassing LB, Hofer SM, Nilsson SE, Berg S, Pedersen NL, McClearn G, Johansson B (2004) Comorbid type 2 diabetes mellitus and hypertension exacerbates cognitive decline: evidence from a longitudinal study. Age Ageing 33(4):355\u2013361","journal-title":"Age Ageing"},{"issue":"4","key":"2382_CR43","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1080\/10253890.2016.1193146","volume":"19","author":"D Havelka","year":"2016","unstructured":"Havelka D, Prikrylova-Kucerova H, Prikryl R, Ceskova E (2016) Cognitive impairment and cortisol levels in first-episode schizophrenia patients. Stress 19(4):383\u2013389","journal-title":"Stress"},{"key":"2382_CR44","doi-asserted-by":"publisher","first-page":"1369532","DOI":"10.3389\/fpsyt.2024.1369532","volume":"15","author":"W Li","year":"2024","unstructured":"Li W, Cao X, Liang Q, Li Y, Zhou C, Du J, Xie S (2024) Gender differences in cognitive improvements after two months of atypical antipsychotic treatment in first episode schizophrenia. Front Psychiatry 15:1369532","journal-title":"Front Psychiatry"},{"key":"2382_CR45","doi-asserted-by":"publisher","first-page":"110380","DOI":"10.1016\/j.pnpbp.2021.110380","volume":"111","author":"L Xia","year":"2021","unstructured":"Xia L, Liu R, Zhou H, Tian Y, Dai Q, Xiu M, Chen D, Wang D, Zhang X (2021) Sex differences in P50 inhibition defects with psychopathology and cognition in patients with first-episode schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 111:110380","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2382_CR46","doi-asserted-by":"publisher","first-page":"742474","DOI":"10.3389\/fendo.2022.742474","volume":"13","author":"W Li","year":"2022","unstructured":"Li W, Lin S, Yue L, Fang Y, Xiao S (2022) Sex differences in obesity and cognitive function in Chinese elderly patients with chronic schizophrenia. Front Endocrinol 13:742474","journal-title":"Front Endocrinol"},{"key":"2382_CR47","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.neubiorev.2015.10.013","volume":"67","author":"A Mendrek","year":"2016","unstructured":"Mendrek A, Mancini-Mar\u00efe A (2016) Sex\/gender differences in the brain and cognition in schizophrenia. Neurosci Biobehav Rev 67:57\u201378","journal-title":"Neurosci Biobehav Rev"},{"issue":"7","key":"2382_CR48","doi-asserted-by":"publisher","first-page":"101652","DOI":"10.1016\/j.xcrm.2024.101652","volume":"5","author":"KJ Bjornson","year":"2024","unstructured":"Bjornson KJ, Vanderplow AM, Bhasker AI, Cahill ME (2024) Increased regional activity of a pro-autophagy pathway in schizophrenia as a contributor to sex differences in the disease pathology. Cell Rep Med 5(7):101652","journal-title":"Cell Rep Med"},{"issue":"2","key":"2382_CR49","doi-asserted-by":"publisher","first-page":"e89428","DOI":"10.1371\/journal.pone.0089428","volume":"9","author":"I Montalvo","year":"2014","unstructured":"Montalvo I, Guti\u00e9rrez-Zotes A, Creus M, Monseny R, Ortega L, Franch J, Lawrie SM, Reynolds RM, Vilella E, Labad J (2014) Increased prolactin levels are associated with impaired processing speed in subjects with early psychosis. PLoS ONE 9(2):e89428","journal-title":"PLoS ONE"},{"issue":"1","key":"2382_CR50","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1586\/14737175.7.1.45","volume":"7","author":"AM Mortimer","year":"2007","unstructured":"Mortimer AM (2007) Relationship between estrogen and schizophrenia. Expert Rev Neurother 7(1):45\u201355","journal-title":"Expert Rev Neurother"},{"issue":"Suppl 23","key":"2382_CR51","first-page":"25","volume":"60","author":"DI Velligan","year":"1999","unstructured":"Velligan DI, Miller AL (1999) Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment. J Clin Psychiatry 60(Suppl 23):25\u201328","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"2382_CR52","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1530\/EC-21-0040","volume":"10","author":"J Liu","year":"2021","unstructured":"Liu J, Zhang L, Fu J, Wang Q, Wang G (2021) Circulating prolactin level is increased in metabolically healthy obesity. Endocr Connect 10(4):484\u2013491","journal-title":"Endocr connections"},{"issue":"4","key":"2382_CR53","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1017\/S0029665117002014","volume":"76","author":"L Dye","year":"2017","unstructured":"Dye L, Boyle NB, Champ C, Lawton C (2017) The relationship between obesity and cognitive health and decline. Proc Nutr Soc 76(4):443\u2013454","journal-title":"Proc Nutr Soc"},{"key":"2382_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajp.2018.11.002","volume":"39","author":"V Wasnik","year":"2019","unstructured":"Wasnik V, Khess CRJ, Munda S, Bijali S (2019) Serum prolactin level and its correlation with psychopathology in drug free\/drug na\u00efve schizophrenia a case control study. Asian J Psychiatry 39:1\u20135","journal-title":"Asian J psychiatry"},{"issue":"1\u20133","key":"2382_CR55","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.schres.2015.09.003","volume":"169","author":"C Shi","year":"2015","unstructured":"Shi C, Kang L, Yao S, Ma Y, Li T, Liang Y, Cheng Z, Xu Y, Shi J, Xu X et al (2015) The MATRICS Consensus Cognitive Battery (MCCB): co-norming and standardization in China. Schizophr Res 169(1\u20133):109\u2013115","journal-title":"Schizophr Res"},{"key":"2382_CR56","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.psyneuen.2018.11.028","volume":"102","author":"J Labad","year":"2019","unstructured":"Labad J (2019) The role of cortisol and prolactin in the pathogenesis and clinical expression of psychotic disorders. Psychoneuroendocrinology 102:24\u201336","journal-title":"Psychoneuroendocrinology"},{"key":"2382_CR57","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.yfrne.2017.06.003","volume":"47","author":"C McGregor","year":"2017","unstructured":"McGregor C, Riordan A, Thornton J (2017) Estrogens and the cognitive symptoms of schizophrenia: possible neuroprotective mechanisms. Front Neuroendocr 47:19\u201333","journal-title":"Front Neuroendocr"},{"issue":"8","key":"2382_CR58","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1159\/000520279","volume":"112","author":"S Mellado","year":"2022","unstructured":"Mellado S, Moreno-Ruiz B, Exp\u00f3sito S, Fern\u00e1ndez M, Mart\u00edn ED (2022) Prolactin reduces hippocampal parvalbumin and GABAA receptor expression in female mice. Neuroendocrinology 112(8):796\u2013806","journal-title":"Neuroendocrinology"},{"issue":"1","key":"2382_CR59","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00441-018-2858-2","volume":"375","author":"J Carretero","year":"2019","unstructured":"Carretero J, S\u00e1nchez-Robledo V, Carretero-Hern\u00e1ndez M, Catalano-Iniesta L, Garc\u00eda-Barrado MJ, Iglesias-Osma MC, Blanco EJ (2019) Prolactin system in the hippocampus. Cell Tissue Res 375(1):193\u2013199","journal-title":"Cell Tissue Res"},{"issue":"9","key":"2382_CR60","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1080\/13803395.2018.1442815","volume":"40","author":"PG Gasquoine","year":"2018","unstructured":"Gasquoine PG (2018) Effects of physical activity on delayed memory measures in randomized controlled trials with nonclinical older, mild cognitive impairment, and dementia participants. J Clin Exp Neuropsychol 40(9):874\u2013886","journal-title":"J Clin Exp Neuropsychol"},{"issue":"1","key":"2382_CR61","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/oxfordjournals.schbul.a033430","volume":"26","author":"MF Green","year":"2000","unstructured":"Green MF, Kern RS, Braff DL, Mintz J (2000) Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the right stuff? Schizophr Bull 26(1):119\u2013136","journal-title":"Schizophr Bull"},{"issue":"5","key":"2382_CR62","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.biopsych.2007.05.022","volume":"63","author":"CR Bowie","year":"2008","unstructured":"Bowie CR, Leung WW, Reichenberg A, McClure MM, Patterson TL, Heaton RK, Harvey PD (2008) Predicting schizophrenia patients\u2019 real-world behavior with specific neuropsychological and functional capacity measures. Biol Psychiatry 63(5):505\u2013511","journal-title":"Biol Psychiatry"},{"key":"2382_CR63","doi-asserted-by":"crossref","unstructured":"Lui SSY, Zhang RT, Lau WYS, Liu ACY, Chui WWH, Wang Y, Tsang KCM, Yeung HKH, Cheung EFC, Chan RCK (2022) Prospective memory influences social functioning in people with first-episode schizophrenia: a network analysis and longitudinal study. J Clin Psychiatry 83(2)","DOI":"10.4088\/JCP.21m14114"},{"issue":"1","key":"2382_CR64","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3171\/jns.1993.79.1.0135","volume":"79","author":"MH Brisman","year":"1993","unstructured":"Brisman MH, Fetell MR, Post KD (1993) Reversible dementia due to macroprolactinoma. Case report. J Neurosurg 79(1):135\u2013137","journal-title":"J Neurosurg"},{"issue":"9","key":"2382_CR65","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/j.psyneuen.2013.02.007","volume":"38","author":"L Moore","year":"2013","unstructured":"Moore L, Kyaw M, Vercammen A, Lenroot R, Kulkarni J, Curtis J, O\u2019Donnell M, Carr VJ, Shannon Weickert C, Weickert TW (2013) Serum testosterone levels are related to cognitive function in men with schizophrenia. Psychoneuroendocrinology 38(9):1717\u20131728","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"2382_CR66","first-page":"010707","volume":"31","author":"N Ruljancic","year":"2021","unstructured":"Ruljancic N, Bakliza A, Vuk Pisk S, Geres N, Matic K, Ivezic E, Grosic V, Filipcic I (2021) Antipsychotics-induced hyperprolactinemia and screening for macroprolactin. Biochemia Med 31(1):010707","journal-title":"Biochemia Med"},{"issue":"1","key":"2382_CR67","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41398-022-02027-4","volume":"12","author":"Z Lu","year":"2022","unstructured":"Lu Z, Sun Y, Zhang Y, Chen Y, Guo L, Liao Y, Kang Z, Feng X, Yue W (2022) Pharmacological treatment strategies for antipsychotic-induced hyperprolactinemia: a systematic review and network meta-analysis. Translational Psychiatry 12(1):267","journal-title":"Translational psychiatry"},{"issue":"10","key":"2382_CR68","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1093\/ajhp\/zxab065","volume":"78","author":"MM Rusgis","year":"2021","unstructured":"Rusgis MM, Alabbasi AY, Nelson LA (2021) Guidance on the treatment of antipsychotic-induced hyperprolactinemia when switching the antipsychotic is not an option. Am J Health Syst Pharm 78(10):862\u2013871","journal-title":"Am J health-system pharmacy: AJHP : official J Am Soc Health-System Pharmacists"},{"key":"2382_CR69","doi-asserted-by":"publisher","first-page":"115138","DOI":"10.1016\/j.psychres.2023.115138","volume":"322","author":"J Cai","year":"2023","unstructured":"Cai J, Li L, Shao T, Sun M, Wang W, Xie P, Wang X, Yang Y, Long Y, Kang D et al (2023) Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics. Psychiatry Res 322:115138","journal-title":"Psychiatry Res"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-026-02382-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-026-02382-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-026-02382-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T08:02:07Z","timestamp":1789804927000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-026-02382-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":69,"alternative-id":["2382"],"URL":"https:\/\/doi.org\/10.1007\/s00406-026-02382-z","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]},"assertion":[{"value":"18 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol for the research project had been approved by the Institutional Review Board (IRB) of the Institute of Psychology, Chinese Academy of Sciences (approval number: H18031), and had therefore been performed following the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients\u2019 informed consent forms were obtained, and their anonymity was protected.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}